The Effect of 3 Different Models of MNT on DM Control in Overweight Patients With T2DM

Obesity Clinical Trial

Official title:

The Effect of Three Different Models of Medical Nutrition Therapy (MNT) on Diabetes Control in Overweight and Obese Patients With Type 2 Diabetes: A Randomized Comparative Study. (Nutrition Path Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02520050
• Other study ID #: CHS#: 2014-40
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: July 2018

Study information

• Verified date: February 2019
• Source: Joslin Diabetes Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The American Diabetes Association (ADA), among other medical societies, is strongly recommending medical nutrition therapy (MNT) for prevention and management of type 2 diabetes. However, the ADA recognized that there is no "one size fits all" diet and thus recommends that MNT should be conducted through a consultation with registered dietitians (RD). Previous studies have shown that using diabetes-specific nutritional formulas, as an integral part of the MNT, lowers postprandial blood glucose levels. Through our experience from the Joslin's Weight Achievement and Intensive Treatment (Why WAIT™) program, applying MNT within a structured dietary intervention protocol has the best impact on blood glucose values and body weight. Meanwhile, the frequent use of health coaching during dietary intervention proved to be effective in managing diabetes and inducing weight loss. However, no study compared those three intervention methods in a randomized clinical study.

The aim of this study is to evaluate the effect of different models of conducting medical nutrition therapy on the glycemic control in patients with type 2 diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: July 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

2. Subject states that he/she had type 2 diabetes, as evidenced by use of anti-hyperglycemic medication or managed on lifestyle intervention only with A1C >7%

3. Subject is between 30 and 80 years of age.

4. Subject on stable dose of antihyperglycemic medications for the past 3 months or lifestyle intervention

5. Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. A urine pregnancy test is required for all female subjects unless she is not of childbearing potential, defined as postmenopausal for at least one year prior to screening visit or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

6. If a female is of childbearing potential, she is practicing one of the following methods of birth control (and continued through the duration of the study):

• Condoms, sponge, diaphragm or intrauterine device;

• Oral or parenteral contraceptives for 3 months prior to screening visit;

• Vasectomized partner;

• Total abstinence from sexual intercourse.

7. Subject's BMI is > 25 kg/m2.

8. Subject has A1C between 7-10%

9. If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, subject has been on stable dose for at least three months prior to screening visit. These medications will not be changed during intervention unless it is mandatory.

Exclusion Criteria:

1. Subjects using exogenous insulin since insulin titration may impact the primary endpoint.

2. Subject states that he/she had a history of diabetic ketoacidosis.

3. Subject is pregnant or lactating.

4. Subject uses corticosteroid treatment with the exception of inhaled or topical steroids in the last 3 months; or antibiotics within the last 3 weeks prior to the screening visit.

5. Subject states that he/she had an active malignancy (excluding the following dermal malignancies: basal cell carcinoma, squamous cell carcinoma, carcinoma in-situ of the cervix).

6. Subject states that he/she has had a recent cardiovascular event (e.g., myocardial infarction, stroke) = six months prior to screening visit; or stated history of congestive heart failure.

7. Subject states that he/she has had end stage organ failure (such as end stage renal disease) or had status post organ transplant.

8. Subject states that he/she has had a history of renal disease (Creatinine >1.5mg/dL or GFR <60 mL/min/1.73 m2).

9. Subject states that he/she has had current hepatic disease.

10. Subject has history of gastroparesis.

11. Subject states that he/she has had a chronic, contagious, infectious disease

12. Subject states that he/she has had clotting or bleeding disorders.

13. Subject is known to be allergic or intolerant to any ingredient found in the study products.

14. Subject is known to have a history of special nutritional need requiring special diet.

15. Subject is currently participating in any weight loss program.

16. Subject has used meal replacements during the 3 months prior to the start of the study.

17. Subject has history of bariatric surgery.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Obesity
• Overweight
• Type 2 Diabetes

Intervention

Behavioral:
• Traditional MNT
Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
• Structured MNT
Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
• Structured MNT plus Weekly Support
Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian

Locations

Country	Name	City	State
United States	Joslin Diabetes Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Joslin Diabetes Center	Metagenics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absolute and relative change in HbA1c		16 weeks
Secondary	Absolute and relative change in body weight		16 weeks
Secondary	Absolute and relative change in fasting blood glucose		16 weeks
Secondary	Absolute and relative change in lipid profile (cholesterol, HDL, LDL, triglycerides)		16 weeks
Secondary	Absolute and relative change in blood pressure		16 weeks
Secondary	Absolute and relative change in High-sensitivity C - reactive protein (hsCRP)		16 weeks
Secondary	Absolute and relative change in HOMA insulin resistance (IR) index		16 weeks
Secondary	Absolute and relative change in c-peptide level		16 weeks
Secondary	Absolute and relative change in microalbumin/creatinine ratio		16 weeks
Secondary	Absolute and relative change in fat mass		16 weeks
Secondary	Absolute and relative change in body fat percentage		16 weeks
Secondary	Absolute and relative change in waist/hip ratio		16 weeks
Secondary	Absolute and relative change in visceral fat content		16 weeks
Secondary	Absolute and relative change in dietary protein		16 weeks
Secondary	Absolute and relative change in energy intake		16 weeks